What is the half-life of desmopressin (DDAVP) when administered subcutaneously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

DDAVP Subcutaneous Half-Life

The elimination half-life of desmopressin (DDAVP) after subcutaneous administration is approximately 3.1 hours in healthy adults. 1

Pharmacokinetic Profile After Subcutaneous Administration

  • Peak plasma concentrations of 480-638 pg/ml are reached approximately 1 hour after subcutaneous injection at a dose of 0.4 μg/kg body weight 1

  • The mean elimination half-life is 3.1 hours following subcutaneous administration, based on direct pharmacokinetic measurements in healthy volunteers 1

  • After intravenous administration (which provides comparative context), the elimination half-life is 78 ± 10 minutes (approximately 1.3 hours), suggesting subcutaneous administration results in a somewhat longer half-life due to absorption kinetics 2

Duration of Clinical Effect vs. Plasma Half-Life

Important clinical distinction: The plasma half-life does not directly correlate with duration of therapeutic effect:

  • Hemostatic effects begin within 1 hour and last 6-8 hours after administration, substantially longer than the plasma half-life 3, 4

  • The antidiuretic effect can persist for up to 12 hours or more after administration, particularly with nighttime dosing 5

  • This prolonged clinical effect occurs because desmopressin triggers release of stored von Willebrand factor and Factor VIII from endothelial cells, and these factors have their own elimination kinetics (half-lives ranging from 1.3-11.4 hours) 1

Dosing Implications

  • Doses can be repeated at 12-24 hour intervals for ongoing hemostatic needs, though tachyphylaxis may occur after 3-5 doses due to depletion of endothelial VWF stores 6

  • The standard subcutaneous dose is 0.3-0.4 μg/kg, which produces therapeutic effects despite the relatively short plasma half-life 6, 3, 4, 1

References

Guideline

Treatment of Uremic Platelet Dysfunction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Desmopressin Dosing for Uremic Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.